PATENT CLAIM ANALYSIS

Application Number: 16131512
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "044000"]

Abstract:
Antisense sequences, including duplex RNAi compositions, which possess improved properties over those taught in the prior art are disclosed. The invention provides optimized antisense oligomer compositions and method for making and using the both in in vitro systems and therapeutically. The invention also provides methods of making and using the improved antisense oligomer compositions.

Claim (Index 31):
A method of treating a patient having a disease involving the expression of a protein, comprising administering to the patient a therapeutically effective amount of the composition of  claim 21 , wherein a strand of the double-stranded oligonucleotide molecule is complementary to a sequence of target nucleic acid involved in expression of the protein, wherein the disease is cancer, retinopathy, an autoimmune disease, an inflammatory disease, a viral disease or a cardiovascular disease.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 97.0
- Lexical Diversity: 1.51282
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15418653', '14446022', '13277957', '15638586', '13147882']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7566310541538646
- 35 USC 102 Novelty (BERT): 0.5683743088351996
- Combined Prediction Score: 0.7378053796219981
- Mean Citation Score: 437.96879
- Max Citation Score: 530.86646
- Similarity Product: 341.2474646875858

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test